HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DEA

This article was originally published in The Rose Sheet

Executive Summary

National Toxicology Program to review diethanolamine for listing in "11th Report on Carcinogens," slated for publication in 2004, NTP announces in July 24 Federal Register notice. Nominated ingredients must be "known to be human carcinogens" or "reasonably anticipated to be human carcinogens" to qualify for listing. NTP will accept comments concerning DEA until Sept. 24. DEA and its esters are used in more than 4,000 personal care products including bubble bath, shampoo and conditioner. Ingredient has been nominated for listing under California Prop 65 and is topic of safety assessment underway at FDA's Office of Cosmetics & Colors

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel